- Celiac Disease & Gluten Intolerance Research
Celiac Disease & Gluten Intolerance Research
A research team wanted to find out if determination of antibodies to synthetic deamidatedgliadin peptides (anti-DGP) might work as an alternative or complement to TGA testing.
A team of researchers set out to determine what factors might influence dissemination of a new and validated commercial Point-of-Care Test (POCT) for celiac disease, in the Mediterranean area, when used in settings where it was designed to be administered, especially in countries with poor resources.
Ghrelin is a peptide that plays an important role in regulating the distribution and rate of use of energy. When the stomach is empty, ghrelin is secreted. When the stomach is stretched, secretion stops.
Doctors recommend medical follow-up of celiac disease patients for gluten-free diet (GFD) adherence monitoring and complication detection. But, what happens to celiac kids who don’t get good medical follow-up?
While the immune response to gluten proteins in celiac disease has been well researched, and is pretty well understood, researchers really don’t know much about the immune response to non-gluten proteins in wheat. A team of researchers recently set out to determine the level and molecular specificity of antibody response to wheat non-gluten proteins in celiac disease.
Symptoms are non-classical in vast majority of people with celiac disease, according to a new study.
The relationship between the risk of celiac disease and both the age at which gluten is introduced to a child’s diet and a child’s early dietary pattern is unclear.
Researchers don’t have much data on rates of celiac disease in patients with autoimmune hepatitis (AIH). To better understand any connections between the two conditions, a Dutch research team recently set out to examine the rates of celiac disease in patients with autoimmune hepatitis.
A team of researchers recently set out to assess the benefits of a gluten-free diet for people whose blood screens show markers for celiac disease, but who show no physical symptoms.
A new drug designed to prevent gluten uptake in the gut is showing some promise for the treatment of celiac disease.
Are hookworms the future of celiac disease treatment? Patients in Australia have shown a major improvement in gluten tolerance after receiving experimental hookworm treatments.
What’s potential celiac disease, and what happens to kids who have it and continue to eat a gluten-containing diet?
Can antibiotic exposure in pregnancy increase the risk of celiac disease in children? Some researchers suspect that infant microbiota play a pathogenic role in celiac disease. The idea that antibiotic treatment in pregnancy could significantly impact the infant microbiota, and thus influence the development of celiac disease, has led many to ponder the possible connection.
In this third study by researcher Peter Gibson at Monash University in Canada, he set out to assess patients claiming to have non-celiac gluten sensitivity.
A study establishing the existence of non-celiac gluten sensitivity has been turned on its head; by the very scientist who conducted it. In 2011, a small but scientifically rigorous study found that dietary gluten can trigger gastrointestinal distress in people without celiac disease. That study was conducted by Peter Gibson at Monash University in Australia.
A research team recently set out to explore the diversity of the cultivable human gut microbiome involved in gluten metabolism.
One angle being tried by researchers to treat celiac disease involves oral peptides that would prevent an adverse gluten reaction in people with celiac disease who are following a gluten-free diet.
People with non-celiac gluten sensitivity (NCGS) do not have celiac disease, but their symptoms improve when they are placed on gluten-free diets.
A research team recently set out to determine the risk of celiac disease autoimmunity and celiac disease, by age and by halpotype, in children.
Each year, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, acetaminophen, and aspirin, send more than 100,000 people to the hospital, and cause over 16,000 deaths. These drugs are marketed under brand names such as Advil, Tylenol, and Bayer, among others.